There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Verve Therapeutics Inc. (VERV) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $23.10. The Verve Therapeutics Inc. has recorded 6,438 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $23.10 and fluctuated between $23.17 as its day high and $21.00 as its day low. The current market capitalization of Verve Therapeutics Inc. is $1.39B. A total of 0.67 million shares were traded on the day, compared to an average of 967.44K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, VERV has seen 2 BUY and 61 SELL insider trades, representing the acquisition of 11,875 and the disposition of 1,073,732 shares. Over the last 12 months, there were 16 BUYs and 87 SELLs from insiders. Insiders purchased 591,336 shares during that period but sold 1,940,297.
In the most recent transaction, Bellinger Andrew sold 865 shares of VERV for 22.95 per share on Dec 01. After the transaction, the CSO & CMO now owns 6,629 company shares. In a previous transaction on Nov 29, Dorval Allison sold 554 shares at 22.10 per share. VERV shares that Chief Financial Officer owns now total 2,186.
Among the insiders who sold shares, GV 2017 GP, L.L.C. disposed of 97,166 shares on Nov 04 at a per-share price of $31.14. This resulted in the Member of 10% Group holding 0 shares of VERV after the transaction. In another insider transaction, Yeshwant Krishna sold 48,583 shares at $31.14 per share on Nov 04. Company shares held by the Director now total 4,260,047.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for VERV in the last 3 months, the mean price target is $43.38 with high estimates of $75.00 and low estimates of $13.00. In terms of 52-week highs and lows, VERV has a high of $43.00 and a low of $10.70.
As of this writing, VERV has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.64 per share and a lower estimate of -$0.87. The company reported an EPS of -$0.62 in the last quarter, which was 6.10% higher than expectations of -$0.66.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VERV is Hold with a score of 4.13. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.